CorMedix Inc. 8-K

What Happened
CorMedix, Inc. (CRMD) filed an 8-K on April 27, 2026 (Accession No. 0001213900-26-047748) under Item 7.01 to disclose a press release providing an update on the initial topline readout of its Phase III ReSPECT study. The study evaluates REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal infections. The press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Press release dated April 27, 2026 was furnished under Item 7.01 (Regulation FD Disclosure).
• Study: Phase III ReSPECT assessing REZZAYO (rezafungin for injection) for antifungal prophylaxis.
• Filing: Form 8-K accession 0001213900-26-047748; Exhibit 99.1 contains the press release.
• Item 9.01 in the filing lists the press release as an exhibit (99.1) and includes the Inline XBRL cover page.

Why It Matters
Topline results from a Phase III trial are a material development for a clinical-stage biopharma company: they provide the first look at whether the drug met primary endpoints for efficacy and safety, and they can shape regulatory timelines, commercialization planning, and investor expectations. CorMedix’s disclosure alerts investors that the initial topline readout is available and that the company is communicating those results publicly via a press release (Exhibit 99.1). Investors should review the press release and any subsequent filings or presentations for the actual topline data and management commentary.